This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lansang, M C. Articles by Hollenberg, N. K Search for Related Content PubMed PubMed Citation Articles by Lansang, M C. Articles by Hollenberg, N. K Social Bookmarking                         What's this?

Effects of the PPAR- Agonist Rosiglitazone on Renal Haemodynamics and the Renin-Angiotensin System in Diabetes

Department of Medicine, University of Florida, Gainesville, FL, USA, lansamc{at}medicine.ufl.edu

Caroline Coletti

Departments of Medicine and Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

Sofia Ahmed

Departments of Medicine and Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

Michael S Gordon

Departments of Medicine and Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

Norman K Hollenberg

Departments of Medicine and Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

Background. Thiazolidinediones (TZD) have been reported to improve early stages of diabetic nephropathy independent of glycaemic control. Since blockade of the renin-angiotensin system (RAS) is known to reduce the risk of nephropathy, we hypothesised that the renal effect of TZDs might be related to a favourable effect on the intrarenal RAS. We aimed to determine if the TZD rosiglitazone could reduce RAS activation.

Methods. We studied adult type 2 diabetic patients and placed them on rosiglitazone for three months. We have previously used the renal haemodynamic response to angiotensin-converting enzyme (ACE) inhibition to demonstrate the state of RAS activation, and thus measured renal plasma flow (RPF) and glomerular filtration rate (GFR) before and after administration of captopril at 0 month and at three months. Plasma renin activity (PRA), active renin, aldosterone and natriuretic peptides were analysed.

Results. The RPF response to ACE inhibition was not altered.There was no change in GFR, PRA, active renin and aldosterone levels. Two patients developed oedema — one had an elevated baseline active renin and another had an elevated baseline aldosterone level.

Conclusion. The favourable effects of TZDs on diabetic nephropathy is likely not related to an influence on the RAS.

Key Words: Diabetes • PPAR-gamma • Thiazolidinedione • Renin-angiotensin system

Journal of Renin-Angiotensin-Aldosterone System, Vol. 7, No. 3, 175-180 (2006)
DOI: 10.3317/jraas.2006.028


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Z. Yousefipour, H. Hercule, L. Truong, A. Oyekan, and M. Newaz Ciglitazone, a Peroxisome Proliferator-Activated Receptor {gamma} Inducer, Ameliorates Renal Preglomerular Production and Activity of Angiotensin II and Thromboxane A2 in Glycerol-Induced Acute Renal Failure J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 461 - 468. [Abstract] [Full Text] [PDF]